title: Double-bullet radioimmunotargeting therapy in 31 primary liver cancer patients.
abstract: OBJECTIVE
  To observe the effect of double bullet immunotargeting therapy with chemotherapy and internal radiotherapy on primary liver cancer.
  
  
  METHODS
  The polyclonal horse antibody against human AFP (anti-AFPAb) and the monoclonal murine antibody against human AFP (anti-AFPMcAb) were used as carriers, and (131)I and mitomycin C (MMC) were used as warheads to form double bullet, i.e. (131)I anti-AFPMcAb-MMC (double bullet 1) and (131)I anti-AFPAb-MMC (double bullet 2) prepared using the modified chloramine T method. Double bullet targeting therapy was administered by intravenous drip once a month in 31 patients (treatment group) with unresectable primary liver cancer. Among them, 4, 17 and 10 patients were administered 1, 2 and 3 times, and the median radiation dose (MBq/case) was 193.5 ± 37.74; 651.9 ± 232.4, and 992.0 ± 230.5 respectively.
  
  
  METHODS
  Tumor shrinkage, decrease in AFP, and 1 and 2 -year survival rates were significantly higher than the control groups who received transarterial infusion (TAI) or transarterial chemoembolization (TACE) at the same time (50.0%, 15/30 vs 30.0%, 9/30, P < 0.05; 66.7%, 18/27 vs 28.0%, 7/25, P < 0.01 and 50.0%, 34.0% vs 33.0%, 3.3%, P < 0.01, respectively). Furthermore, the tumor progression rate (10%) in the treatment group was significantly lower than that of the control group (40.0%, P < 0.01).
  
  
  CONCLUSIONS
  Double bullet target therapy is more effective than traditional therapies due to the synergistic effects of the antibody, radioisotope, and anticancer agents, which together, enhance tumor killing.
authors.affiliation: Ying-De Wu, Xiao-Hua Hu, Zhi-Ge Li, Xiang-Qun Song, Ke-Zheng Yang, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China.
authors.forename: Y D
authors.initials: YD
authors.lastname: Wu
authors.affiliation: Ying-De Wu, Xiao-Hua Hu, Zhi-Ge Li, Xiang-Qun Song, Ke-Zheng Yang, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China.
authors.forename: D N
authors.initials: DN
authors.lastname: Zhou
authors.affiliation: Ying-De Wu, Xiao-Hua Hu, Zhi-Ge Li, Xiang-Qun Song, Ke-Zheng Yang, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China.
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Gang
authors.affiliation: Ying-De Wu, Xiao-Hua Hu, Zhi-Ge Li, Xiang-Qun Song, Ke-Zheng Yang, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China.
authors.forename: X H
authors.initials: XH
authors.lastname: Hu
authors.affiliation: Ying-De Wu, Xiao-Hua Hu, Zhi-Ge Li, Xiang-Qun Song, Ke-Zheng Yang, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China.
authors.forename: Z G
authors.initials: ZG
authors.lastname: Li
authors.affiliation: Ying-De Wu, Xiao-Hua Hu, Zhi-Ge Li, Xiang-Qun Song, Ke-Zheng Yang, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China.
authors.forename: X Q
authors.initials: XQ
authors.lastname: Song
authors.affiliation: Ying-De Wu, Xiao-Hua Hu, Zhi-Ge Li, Xiang-Qun Song, Ke-Zheng Yang, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China.
authors.forename: H P
authors.initials: HP
authors.lastname: He
authors.affiliation: Ying-De Wu, Xiao-Hua Hu, Zhi-Ge Li, Xiang-Qun Song, Ke-Zheng Yang, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China.
authors.forename: K Z
authors.initials: KZ
authors.lastname: Yang
authors.affiliation: Ying-De Wu, Xiao-Hua Hu, Zhi-Ge Li, Xiang-Qun Song, Ke-Zheng Yang, Bing-Yan Huang, Department of Chemotherapy, Affiliated Cancer Hospital, Guangxi Medical University, Nanning 530021, Guangxi Province, China.
authors.forename: B Y
authors.initials: BY
authors.lastname: Huang
keywords: Alpha fetoproteins; Antibodies, monoclonal; Immunotherapy; Liver neoplasms/therapy